PSI

• UNSPSC Description:

  PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1].

• Target Antigen:

  Proteasome

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/psi.html

• Purity:

  97.0

• Solubility:

  H2O : < 0.1 mg/mL (adjust pH to 2 with Acetic acid)

• Smiles:

  O=C([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)N[C@@H](CCC(OC(C)(C)C)=O)C(N[C@@H](C)C(N[C@H](C=O)CC(C)C)=O)=O

• Molecular Weight:

  618.76

• References & Citations:

  [1]Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  158442-41-2